Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
The US Court of Appeals for the Federal Circuit yesterday, May 8, rejected an appeal from Amgen in patent litigation relating to two Sandoz biosimilars.
A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.
The US Court of Appeals for the Federal Circuit affirmed a series of Patent Trial and Appeal Board inter partes reviews, which upheld a patent owned by Eli Lilly late last week.
US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.
A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.
The European Parliament has voted to approve the supplementary protection certificate manufacturing waiver, which will allow the stockpiling of generic versions of patented drugs.
Plans by Canada’s government to improve access to generic drugs could deter pharmaceutical companies from releasing brand medicine in the country, according to an internal government report.
The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Amgen subsidiary Immunex has appealed against a Patent Trial and Appeal Board decision which invalidated a patent claiming antibodies that target human interleukin-4 receptors.